Research groups

GC05 Systemic and chronic inflammatory autoimmune diseases of the locomotor system and connective tissue

Our team is integrated in the Scientific Program on Chronic and Inflammatory Diseases, oriented to the study of the most relevant chronic processes of the modern society, with special emphasis on those of an inflammatory and autoimmune nature. This area mainly covers the study of chronic inflammatory and systemic autoimmune diseases, cardiovascular diseases, neurological diseases, renal and urological diseases, liver and digestive diseases.

Our research team employs synergistically clinical-therapeutic approaches and cellular and molecular approaches, and has as main objectives to:

  1. Analyze molecular and cellular mechanisms of atherothrombosis development in systemic autoimmune diseases (EAS), and to identify new biomarkers and regulatory mechanisms promoted by new therapeutic approaches.
  2. Analyze the role of the chronic systemic inflammation in the glucose and lipid metabolism in rheumatoid and psoriatic arthritis.
  3. Study of the effects of conventional therapies (DMARDs), new agents (Apremilast) and other biologic drugs (anti-TNFa) on the metabolic syndrome associated with chronic inflammatory diseases.
  4. Record, describe, and analyze clinical, epidemiological, demographic, genetic, radiographic, pathophysiological and of therapeutic response in patients with spondyloarthritis (AS) in Spain.
  5. Design, develop and validate a new system of measurement of mobility (most important expression of structural damage) of AS patients.

Ours research contributes to improved patient care by adding to our knowledge and discovering new biological therapies for e.g. Rheumatoid Arthritis, Spondyloarthritis, or for other Autoimmune Diseases. New biological therapies are selected for patients who do not respond adequately to conventional treatments. The biological therapy helps chronic patients to spend long asymptomatic periods, and to reduce disease outbreaks. This allows better control of these diseases, as well as improved prognosis and quality of life of patients and, therefore, a modern and effective alternative in cases of difficult control of the rheumatologic diseases.

We have long-lasting and wide network of collaborations with researchers at the St. Thomas NHS Foundation Trust (UK), University of Cambridge (UK), IDIVAL, Genyo, University of Murcia, and Center of Research of Immunopathology and Rare Diseases (Italy), among others.

Research Lines

Our team studies the cellular and molecular mechanisms of atherothrombosis development and organ damage in three systemic autoimmune diseases: Systemic Lupus Erythematosus (SLE), Antiphospholipid syndrome (APS) and Rheumatoid Arthritis (RA). We further analyze the regulatory mechanisms promoted by new therapeutic approaches such as Statins, biological therapies (i.e. anti-TNF, anti-IL6, anti-Blyss), biosimilars, and new drugs with antioxidant and anti-inflammatory effects (i.e. Coenzyme Q10, cannabinoids).

Our research group also investigates new molecular biomarkers involved in the development of systemic autoimmune diseases. Specifically, the group conducts various research projects among which we can highlight PRECISESADS (Molecular Reclassification to Find clinically Useful Biomarkers for Systemic Autoimmune Diseases), a European project funded by the Innovative Medicines Initiative (IMI).

The aim of PRECISESADS is the use of -omics and bioinformatics tools for the reclassification of EAS that share common pathophysiological mechanisms. The project aims to push for personalized medicine based on clinical and molecular profiles of the individual by promoting a substantial improvement in the processes of prediction, diagnosis, and clinical developments as well as in monitoring therapeutic response.

This project, recently finished, will be continued by a recently granted new European project: Taxonomy, Treatment, Targets and Remission (3TR) which main objective is the Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions. This study will last from October 2019 to October 2026.

Metabolic disorders are strongly associated with systemic autoimmune and chronic inflammatory diseases. Our group has recently started a new research area focused on the study of the mechanisms involved in the development of metabolic co morbidities in rheumatoid and psoriatic arthritis.

The main objectives within this area are to analyze the role of the chronic systemic inflammation in the glucose and lipid metabolism in rheumatoid and psoriatic arthritis, and to study the effect of conventional therapies (DMARDs), new agents (Apremilast) and other biologic drugs (anti-TNFa) on the metabolic syndrome associated with chronic inflammatory diseases.

Our group has 3 lines of research in this field:

  • Clinical and epidemiological aspects of spondylarthritis (SPA) (activity and disease severity) at local, national (Spanish Registry EA: REGISPONSER) and international levels (European and Latin American Registry of EA (E: RESPONDIA).
  • Development of a new system for evaluating the mobility of patients with AS (as an expression of structural damage and disease severity) by informatics technologies developed by our group (UCOTRACK. computerized motion capture using artificial vision; patented).
  • Study of the cellular and molecular mechanisms of the inflammatory and osteoproliferative pathways, in order to find new therapeutic targets.

Networks

Keywords

  • Autoimmune diseases
  • spondiloarthropathies
  • inflammation
  • atherothrombosis
  • metabolic syndrome
  • organ damage
  • biomarkers
  • new therapies

Additional Information

Our website: PASIC

Relevant articles

1. Perez-Sanchez C, Cecchi I, Barbarroja N, Patino-Trives AM, Luque-Tevar M, Perez-Sanchez L, Ibanez-Costa A, de la Rosa IA, Ortega R, Escudero A, Castro MC, Radin M, Roccatello D, Sciascia S, Aguirre MA, Collantes E, Lopez-Pedrera C. Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2019. 23. 9. 6308-6318. DOI:10.1111/jcmm.14517. IF: 4,658. Q1. Article; Early Access. IMIBIC GROUPS: GC05

2. Ruiz-Limon P, Ortega-Castro R, Barbarroja N, Perez-Sanchez C, Jamin C, Patino-Trives AM, Luque-Tevar M, Ibanez-Costa A, Perez-Sanchez L, de la Rosa IA, Abalos-Aguilera M, Jimenez-Gomez Y, Calvo-Gutierrez J, Font P, Escudero-Contreras A, Alarcon-Riquelme M. Molecular Characterization of Monocyte Subsets Reveals Specific and Distinctive Molecular Signatures Associated With Cardiovascular Disease in Rheumatoid Arthritis. FRONTIERS IN IMMUNOLOGY. 2019. 10. DOI:10.3389/fimmu.2019.01111.  IF: 4,716. Q2. Article. IMIBIC GROUPS: GC05

3. Lopez-Pedrera C, Barbarroja N, Patino-Trives AM, Collantes E, Aguirre MA, Perez-Sanchez C. New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches. FRONTIERS IN IMMUNOLOGY. 2019. 10. DOI:10.3389/fimmu.2019.00764. IF: 4,716. Q2. Review. IMIBIC GROUPS: GC05

4. Sanmarti R, Veale DJ, Martin-Mola E, Escudero-Contreras A, González C, Ercole L, Alonso R, Fonseca JE; ToSpace Study Group. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial. Arthritis & Rheumatology. 2019 Oct. Doi: 10.1002/art.40905. IF: 9.002 Q1/D1 Article. IMIBIC GROUPS: GC05

5. Lopez-Isac E, Acosta-Herrera M, Kerick M, Assassi S, Satpathy AT, Granja J, Mumbach MR, Beretta L, Simeon CP, Carreira P, Ortego-Centeno N, Castellvi I, Bossini-Castillo L, Carmona FD, Orozco G, Hunzelmann N, Distler JHW, Franke A, Lunardi C, Moroncini G, Gabrielli A, de Vries-Bouwstra J, Wijmenga C, Koeleman BPC, Nordin A, Padyukov L, Hoffmann-Vold AM, Lie B.  European Scleroderma Grp; ASIG: Rios, R; Callejas, JL; Vargas-Hitos, JA; Garcia-Portales, R; Camps, MT; Fernandez-Nebro, A; Gonzalez-Escribano, MF; Garcia-Hernandez, FJ; Castillo, MJ; Aguirre, MA; Gomez-Gracia, I; Fernandez-Gutierrez, B; Rodriguez-Rodriguez, L; de la Pena, PG; Vicente, E; Andreu, JL; de Castro, MF; Lopez-Longo, FJ; Martinez, L; Fonollosa, V; Guillen, A; Espinosa, G; Tolosa, C; Pros, A; Rodriguez-Carballeira, M; Narvaez, FJ; Rubio-Rivas, M; Ortiz-Santamaria, V; Madronero, AB; Gonzalez-Gay, MA; Diaz, B; Trapiella, L; Sousa, A; Egurbide, MV; Fanlo-Mateo, P; Saez-Comet, L; Diaz, F; Hernandez, V; Beltran, E; Roman-Ivorra, JA; Grau, E; Alegre-Sancho, JJ; Freire, M; Blanco-Garcia, FJ; Oreiro, N; Witte, T; Kreuter, A; Riemekasten, G; Airo, P; Magro, C; Voskuyl, AE; Vonk, MC; Hesselstrand, R; Proudman, S; Stevens, W; Nikpour, M; Zochling, J; Sahhar, J; Roddy, J; Nash, P; Tymms, K; Rischmueller, M; Lester, S; Vyse, T; Herrick, AL; Worthington, J; Denton, CP; Allanore, Y; Brown, MA; Radstake, TRDJ; Fonseca, C; Chang, HY; Mayes, MD; Martin, JGWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. Nature Communications. 2019 Oct 31. Doi: 10.1038/s41467-019-12760-y. IF: 11.878 Q1/D1. Article.IMIBIC GROUPS: GC05

6. Cecchi I, Arias de la Rosa I, Menegatti E, et al. Neutrophils: Novel key players in Rheumatoid Arthritis. Current and future therapeutic targets. Autoimmun Rev. 2018 Nov;17(11):1138-1149. doi: 10.1016/j.autrev.2018.06.006. Epub 2018 Sep 11. Review.

7. Del Rio C, Cantarero I, Palomares B, Gómez-Cañas M, et al. VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways. Br J Pharmacol. 2018 Oct;175(19):3813-3831. doi: 10.1111/bph.14450. Epub 2018 Aug 23.

8. Pérez-Sánchez C, Arias-de la Rosa I, Aguirre MÁ, et al. Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome.  Haematologica. 2018 May;103(5):908-918. doi: 10.3324/haematol.2017.184416. Epub 2018 Mar 15.

9. Arias de la Rosa I, Escudero-Contreras A, Rodríguez-Cuenca S, et al. Defective glucose and lipid metabolism in rheumatoid arthritis is determined by chronic inflammation in metabolic tissues. J Intern Med. 2018 Jul;284(1):61-77. doi: 10.1111/joim.12743. Epub 2018 Mar 12.

10. Perez-Sanchez C, Font-Ugalde P, Ruiz-Limon P,  et al. Circulating microRNAs as potential biomarkers of disease activity and structural damage in ankylosing spondylitis patients. Hum Mol Genet. 2018 Mar 1;27(5):875-890. doi: 10.1093/hmg/ddy008.

11. Pérez-Sánchez C, Aguirre MÁ, Ruiz-Limón P, et al. Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile: A Randomized, Placebo-Controlled Trial. Arterioscler Thromb Vasc Biol. 2017 Oct;37(10):1923-1932. doi: 10.1161/ATVBAHA.117.309225. Epub 2017 Jul 6.

12. Pérez-Sánchez C, Ruiz-Limón P, Aguirre MA, et al. Diagnostic potential of NETosis derived products for disease activity, atherosclerosis and therapeutic effectiveness in Rheumatoid Arthritis patients. J Autoimmun. 2017 Aug;82:31-40. doi: 10.1016/j.jaut.2017.04.007. Epub 2017 Apr 29

13. Pérez-Sánchez C, Aguirre MA, Ruiz-Limón P, et al. Atherothrombosis associated microRNAs in Antiphospholipid syndrome and Systemic Lupus erythematosus patients. Sci Rep. 2016 Aug 9;6:31375. doi: 10.1038/srep31375

14. Ruiz-Limón P, Ortega R, Arias de la Rosa I, et al. Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis and inflammation. Transl Res. 2017 May;183:87-103. doi: 10.1016/j.trsl.2016.12.003. Epub 2016 Dec 9

15. Castro-Villegas C, Pérez-Sánchez C, Escudero A, et al. Circulating miRNAs as potential biomarkers of therapy effectiveness in Rheumatoid Arthritis patients treated with antiTNFα. Arthritis Res Ther. 2015 Mar 9;17:49. doi: 10.1186/s13075-015-0555-z.

16. Perez-Sanchez C, Barbarroja N, Messineo S, et al. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipidsyndrome with lupus. Ann Rheum Dis. 2015 Jul;74(7):1441-9. doi: 10.1136/annrheumdis-2013-204600. Epub 2014 Mar 11

17. Ruiz-Limon P, Barbarroja N, Perez-Sanchez C, et al. Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. Ann Rheum Dis. 2015 Jul;74(7):1450-8. doi: 10.1136/annrheumdis-2013-204351. Epub 2014 Mar 21

18. Barbarroja N, Pérez-Sanchez C, Ruiz-Limon P, et al. Anticyclic citrullinated protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis. Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2706-16. doi: 10.1161/ATVBAHA.114.304475. Epub 2014 Sep 25

19. Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, et al. Mitochondrial dysfunction in Antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment. Blood. 2012 Jun 14;119(24):5859-70. doi: 10.1182/blood-2011-12-400986. Epub 2012 Apr 23.

20. López-Pedrera C, Ruiz-Limón P, Aguirre MÁ, et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis. 2011 Apr;70(4):675-82. doi: 10.1136/ard.2010.135525. Epub 2010 Dec 20.

Patents

Título propiedad industrial registrada: Método de obtención de datos útiles para el diagnóstico, estratificación y/o seguimiento de pacientes con artritis reumatoide.
Inventores/autores/obtentores: Rosario López Pedrera; Raul Luque Huertas, Carlos Perez-Sanchez, Eduardo Collantes Estevez, Rafaela Ortega Castro, Justo Pastor Castaño Fuentes, Alejandro Ibañez Costa, Sergio Pedraza Arevalo, Mercedes del Rio Moreno, Nuria Barbarroja Puerto, Yolanda Jimenez Gomez.
Entidad titular de derechos: Servicio Andaluz de Salud y Universidad de Córdoba. 
Nº de solicitud: P201930123.
País de inscripción: España, Andalucía.
Fecha de registro: 15/02/2019

Título propiedad industrial registrada: MiRNAs circulantes como biomarcadores del Síndrome Antifosfolípido Primario.
Inventores/autores/obtentores: Rosario López Pedrera; María Ángeles Aguirre Zamorano; Eduardo Collantes Estévez; Nuria Barbarroja Puerto; Carlos Pérez Sánchez; Yolanda Jiménez Gómez. 
Entidad titular de derechos: Servicio Andaluz de Salud, Universidad de Córdoba. 
Nº de solicitud: P201630725.
País de inscripción: España, Andalucía.
Fecha de registro: 01/06/2016

Título propiedad industrial registrada: MiRNAs como biomarcadores para el diagnóstico de cáncer de pulmón. 
Inventores/autores/obtentores: Antonio Rodríguez Ariza, Rosario López Pedrera; Nuria Barbarroja Puerto; Carlos Pérez Sánchez.
Entidad titular de derechos: Servicio Andaluz de Salud, Universidad de Córdoba. 
Nº de solicitud: P201630628.
País de inscripción: España, Andalucía.
Fecha de registro: 13/03/2016.

Título propiedad industrial registrada: MiRNAs circulantes como biomarcadores de efectividad terapéutica en pacientes con Artritis Reumatoide tratados con anti-TNFalpha. 
Inventores/autores/obtentores: Rosario López Pedrera; Carlos Pérez Sánchez; Carmen Castro Villegas; Eduardo Collantes Estévez; Nuria Barbarroja Puerto; Patricia Ruiz Limón; Yolanda Jiménez Gómez
Entidad titular de derechos: Fundación Progreso y Salud.
Nº de solicitud: EP14382178.3.
País de inscripción: España, Andalucía.
Fecha de registro: 22/05/2014.

Título propiedad industrial registrada: Dispositivo y métodos de captura y análisis de movimiento. 
Inventores/autores/obtentores: Eduardo Collantes Estévez, Juan Luis Garrido Castro 
Entidad titular de derechos: Servicio Andaluz de Salud, Universidad de Córdoba. 
Nº de solicitud: RPI201399901094447.
País de inscripción: España, Andalucía.
Fecha de registro: 08/10/2013.

Título propiedad industrial registrada: Dispositivo y métodos de captura y análisis de movimiento UCOTRACK. 
Inventores/autores/obtentores: Eduardo Collantes Estévez, Juan Luis Garrido Castro
Entidad titular de derechos: Servicio Andaluz de Salud, Universidad de Córdoba. 
Nº de solicitud: P201130413.
País de inscripción: España, Andalucía.
Fecha de registro: 22/03/2011.

Relevant projects

  1. Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions. 3TR. 
  2. Implicación de la microbiota intestinal en la progresión radiográfica en pacientes con Espondiloartritis axial. PI19/00701
  3. Desarrollo y validación del uso de sensores inerciales aplicados a la metrología de pacientes con espondiloartritis axial.. Funding agency: Institute Carlos III Health (ISCIII).  Reference: DTS18/00046. 2019-2021                  
  4. Identification of the molecular heterogeneity associated with cardiovascular disease, clinical evolution and therapeutic response in systemic autoimmune pathologies. PI18/00837. 2019-2021.
  5. Study of the epigenetic mechanisms involved in the development of insulin resistance and obesity associated with rheumatoid arthritis and psoriatic arthritis Funding agency: Institute Carlos III Health (ISCIII).  PI17/01316. 2018-2020.
  6. Molecular reclassification to find clinically useful biomarkers for systemic autoinmunediseases (PRECISESADS)  IMI 15565. 2014-2019.

GC05 Systemic and chronic inflammatory autoimmune diseases of the locomotor system and connective tissue

Principal Investigator
Rosario López Pedrera

Co-Principal Investigator
Eduardo Collantes Estévez

Emerging Researcher
Nuria Barbarroja Puerto

Researchers
Mª Ángeles Aguirre Zamorano
Miguel Ángel Caracuel Ruiz
Alejandro Escudero Contreras
Pilar Font Ugalde
Inmaculada Gómez Gracia
María Dolores López Montilla
Verónica Pérez Guijo

Post-Doctoral Researchers
Jerusalem Calvo Gutierrez
Mª Del Carmen Castro Villegas
Alejandro Ibañez Costa
Yolanda Jiménez Gómez
Clementina López Medina
Rafaela Ortega Castro
Carlos Pérez Sánchez

Pre-Doctoral Researchers
Alejandra Maria Patiño Trives
Iván Arias de la Rosa
Luis Jurado Ruiz
Rocío Segura Ruiz

Technical, Nursing and Administrative Staff
Mª Carmen Ábalos Aguilera
María Dolores Romero Gutiérrez
Desiree Ruiz Vílchez
 

Projects

Active projects

Regional

Jiménez Gómez, Y. Nuevos Mecanismos de Regulación Génica Post-Transcripcional Involucrados en la Patogenia de la Espondilitis Anquilosante (Ea): Micrornas y Splicing Alternativo. Nuevas AproximacionesTerapéuticas. Funding agency: Regional Ministry of Equality, Health and Social Policies (CISPS).  Reference: PI-0139-2017             

Aguirre Zamorano, Mª A. Identificación y Caracterización de Nuevos Biomarcadores Como Predictores de Respuesta A Terapias Biologicas en la Artritis Reumatoide. Funding agency: Regional Ministry of Equality, Health and Social Policies (CISPS).  Reference: PI-0285-2017

Alburquerque Sendín, F. Evaluación Clinimétrica de Los Sensores Inerciales de Movimiento en la Columna Cervical de Pacientes Con Parálisis Cerebral: Validez, Fiabilidad y Patrones de Comportamiento. Funding agency: Regional Ministry of Equality, Health and Social Policies (CISPS).  Reference: PI-0324-2017          

National

Collantes Estévez, E. Implicación de la microbiota intestinal en la progresión radiográfica en pacientes con Espondiloartritis axial. PI19/00701

Lopez Pedrera, R. Identification of the molecular heterogeneity associated with cardiovascular disease, clinical evolution and therapeutic response in systemic autoimmune pathologies. PI18/00837

Collantes Estevez, E. Spanish Network for Research in inflammation and rheumatic disease (RIER). Funding agency: Institute Carlos III Health (ISCIII). Reference: RD16/0012/0015     

Barbarroja Puerto, N – Escudero Contreras, A. Study of the epigenetic mechanisms involved in the development of insulin resistance and obesity associated with rheumatoid arthritis and psoriatic arthritis Funding agency: Institute Carlos III Health (ISCIII).  Reference: PI17/01316

Collantes Estevez, E. Development and validation of the use of inertial sensors applied to the metrology of patients with axial spondyloarthritis. Funding agency: Institute Carlos III Health (ISCIII).  Reference: DTS18/00046

International

Collantes Estevez, E. Can Inertial Movement Sensors (IMUs) provide a valid and reliable way of measuring Spinal Mobility in Axial Spondyloarthritis (axSpa): a Clinimetric Evaluation. Funding Agency: Foundation for Research in Rheumatology. Reference: FOREUM-2015-001

Collantes Estevez, E. 3TR - Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions. General coordinator: Marta Alarcón-Riquelme, FPS. Financial entity: Innovative Medicined Initiative (IMI) – EU + EFPIA. Reference: 831434. Duration: 01/09/2019-31/08/2026. Budget IMIBIC: 900.000 € (Collaborative project, global Budget: 80 million €)

Publications

Main Publications 2019

Perez-Sanchez C, Cecchi I, Barbarroja N, Patino-Trives AM, Luque-Tevar M, Perez-Sanchez L, Ibanez-Costa A, de la Rosa IA, Ortega R, Escudero A, Castro MC, Radin M, Roccatello D, Sciascia S, Aguirre MA, Collantes E, Lopez-Pedrera C. Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2019. 23. 9. 6308-6318. DOI:10.1111/jcmm.14517.
IF: 4,658
Q: 1

Ruiz-Limon P, Ortega-Castro R, Barbarroja N, Perez-Sanchez C, Jamin C, Patino-Trives AM, Luque-Tevar M, Ibanez-Costa A, Perez-Sanchez L, de la Rosa IA, Abalos-Aguilera M, Jimenez-Gomez Y, Calvo-Gutierrez J, Font P, Escudero-Contreras A, Alarcon-Riquelme M. Molecular Characterization of Monocyte Subsets Reveals Specific and Distinctive Molecular Signatures Associated With Cardiovascular Disease in Rheumatoid Arthritis. FRONTIERS IN IMMUNOLOGY. 2019. 10. DOI:10.3389/fimmu.2019.01111.
IF: 4,716
Q: 2

Lopez-Pedrera C, Barbarroja N, Patino-Trives AM, Collantes E, Aguirre MA, Perez-Sanchez C. New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches. FRONTIERS IN IMMUNOLOGY. 2019. 10. DOI:10.3389/fimmu.2019.00764.
IF: 4,716
Q: 2

Sanmarti R, Veale DJ, Martin-Mola E, Escudero-Contreras A, González C, Ercole L, Alonso R, Fonseca JE; ToSpace Study Group. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial. Arthritis & Rheumatology. 2019 Oct. Doi: 10.1002/art.40905.
IF: 9.002
Q: 1 D: 1

Lopez-Isac E, Acosta-Herrera M, Kerick M, Assassi S, Satpathy AT, Granja J, Mumbach MR, Beretta L, Simeon CP, Carreira P, Ortego-Centeno N, Castellvi I, Bossini-Castillo L, Carmona FD, Orozco G, Hunzelmann N, Distler JHW, Franke A, Lunardi C, Moroncini G, Gabrielli A, de Vries-Bouwstra J, Wijmenga C, Koeleman BPC, Nordin A, Padyukov L, Hoffmann-Vold AM, Lie B.  European Scleroderma Grp; ASIG: Rios, R; Callejas, JL; Vargas-Hitos, JA; Garcia-Portales, R; Camps, MT; Fernandez-Nebro, A; Gonzalez-Escribano, MF; Garcia-Hernandez, FJ; Castillo, MJ; Aguirre, MA; Gomez-Gracia, I; Fernandez-Gutierrez, B; Rodriguez-Rodriguez, L; de la Pena, PG; Vicente, E; Andreu, JL; de Castro, MF; Lopez-Longo, FJ; Martinez, L; Fonollosa, V; Guillen, A; Espinosa, G; Tolosa, C; Pros, A; Rodriguez-Carballeira, M; Narvaez, FJ; Rubio-Rivas, M; Ortiz-Santamaria, V; Madronero, AB; Gonzalez-Gay, MA; Diaz, B; Trapiella, L; Sousa, A; Egurbide, MV; Fanlo-Mateo, P; Saez-Comet, L; Diaz, F; Hernandez, V; Beltran, E; Roman-Ivorra, JA; Grau, E; Alegre-Sancho, JJ; Freire, M; Blanco-Garcia, FJ; Oreiro, N; Witte, T; Kreuter, A; Riemekasten, G; Airo, P; Magro, C; Voskuyl, AE; Vonk, MC; Hesselstrand, R; Proudman, S; Stevens, W; Nikpour, M; Zochling, J; Sahhar, J; Roddy, J; Nash, P; Tymms, K; Rischmueller, M; Lester, S; Vyse, T; Herrick, AL; Worthington, J; Denton, CP; Allanore, Y; Brown, MA; Radstake, TRDJ; Fonseca, C; Chang, HY; Mayes, MD; Martin, JGWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. Nature Communications. 2019 Oct 31. Doi: 10.1038/s41467-019-12760-y.
IF: 11.878
Q: 1 D:1

Main Publications 2018

Cecchi I, Arias de la Rosa I, Menegatti E, et al. Neutrophils: Novel key players in Rheumatoid Arthritis. Current and future therapeutic targets. Autoimmun Rev. 2018 Nov;17(11):1138-1149. doi: 10.1016/j.autrev.2018.06.006. 2018 Sep 11. Review.
IF: 8.745
Q: 1   D: 1

Pérez-Sánchez C, Arias-de la Rosa I, Aguirre MÁ, et al. Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome.  Haematologica. 2018 May;103(5):908-918. doi: 10.3324/haematol.2017.184416. Epub 2018 Mar 15.
IF: 9,09  
Q: 1   D: 1

Arias de la Rosa I, Escudero-Contreras A, Rodríguez-Cuenca S, et al. Defective glucose and lipid metabolism in rheumatoid arthritis is determined by chronic inflammation in metabolic tissues. J Intern Med. 2018 Jul;284(1):61-77. doi: 10.1111/joim.12743. Epub 2018 Mar 12.
IF: 6,754  
Q: 1   D: 1

Perez-Sanchez C, Font-Ugalde P, Ruiz-Limon P,  et al. Circulating microRNAs as potential biomarkers of disease activity and structural damage in ankylosing spondylitis patients. Hum Mol Genet. 2018 Mar 1;27(5):875-890. doi: 10.1093/hmg/ddy008.
IF: 4,902  
Q: 1

Other Publications 2018

López-Mejías R, Carmona FD, Genre F, et al. A genome-wide association study identifies a 3'UTR genetic variant of RARB associated with carotid intima-media thickness in rheumatoid arthritis. Arthritis Rheumatol. 2018 Sep 24. doi: 10.1002/art.40734.
IF:  7.873 
Q:1   D: 1

Lopez-Medina C, Garrido-Castro JL, Castro-Jimenez J, Gonzalez-Navas C, Calvo-Gutierrez J, Castro-Villegas MC, Ortega-Castro R, Escudero-Contreras A, Font-Ugalde P, Collantes-Estevez E. Evaluation of quality of life in patients with axial spondyloarthritis and its association with disease activity, functionality, mobility, and structural damage. CLINICAL RHEUMATOLOGY. 2018; 37(6):1581-1588.
IF: 2,141  
Q: 3

Del Rio C, Cantarero I, Palomares B, Gómez-Cañas M, et al. VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways. Br J Pharmacol. 2018 Oct;175(19):3813-3831. doi: 10.1111/bph.14450. Epub 2018 Aug 23.
IF: 6.810
Q: 1   D: 1

Arevalo M, Masmitja JG, Moreno M, Calvet J, Orellana C, Ruiz D, Castro C, Carreto P, Larrosa M, Collantes E, Font P. Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONSER database. ARTHRITIS RESEARCH & THERAPY. 2018; 20:Núm artículo 221
IF: 4,269  
Q: 2

Lopez-Medina C, Jimenez-Gomez Y, Molto A, Schiotis RE, Marzo-Ortega H, van Gaalen FA, Ozgocmen S, Dougados M, Calvo-Gutierrez J, Castro-Villegas MC, Collantes-Estevez E, Font-Ugalde P. Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA project. JOINT BONE SPINE. 2018; 85(4):447-453.
IF: 3,304  
Q: 2

Lopez-Medina C, Molto A. Update on the epidemiology, risk factors, and disease outcomes of axial spondyloarthritis. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY.2018; 32(2):241-253.
IF: 3,198  
Q: 2

Martin-Varillas JL, Calvo-Rio V, Beltran E, Sanchez-Burson J, Mesquida M, Adan A, Hernandez MV, Garfella MH, Pascual EV, Martinez-Costa L, Sellas-Fernandez A, Cordero-Coma M, Diaz-Llopis M, Gallego R, Salom D, Ortego N, Garcia-Serrano JL, Callejas-Rubio JL, Herreras JM, Garcia-Aparicio A, Maiz O, Blanco A, Torre I, Diaz-Valle D, Pato E, Aurrecoechea E, Caracuel MA, Gamero F, Minguez E, Carrasco-Cubero C, Olive A, Vazquez J, Ruiz-Moreno O, Manero J, Munoz-Fernandez S, Martinez MG, Rubio-Romero E, de Miera FJTS, Longo FJL, Nolla JM, Revenga M, Gonzalez-Vela C, Loricera J, Atienza-Mateo B, Demetrio-Pablo R, Hernandez JL, Gonzalez-Gay MA, Blanco R. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behcet's Disease. OPHTHALMOLOGY. 2018; 125(9):1444-1451.
IF: 7,479  
Q: 1   D: 1

del Rio C, Cantarero I, Palomares B, Gomez-Canas M, Fernandez-Ruiz J, Pavicic C, Garcia-Martin A, Bellido ML, Ortega-Castro R, Perez-Sanchez C, Lopez-Pedrera C, Appendino G, Calzado MA, Munoz E. VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPAR gamma- and CB2 receptor-dependent pathways. BRITISH JOURNAL OF PHARMACOLOGY. 2018; 175(19):3813-3831.
IF: 6,81  
Q: 1   D: 1

Lopez-Medina C, Dougados M, Collantes-Estevez E, Molto A. Adherence to recommendations for the use of anti-tumour necrosis factor and its impact over 5 years of follow-up in axial spondyloarthritis. RHEUMATOLOGY. 2018; 57(5):880-890.
IF: 5,245  
Q:1   D: 2

Travez A, Rabanal-Ruiz Y, Lopez-Alcala J, Molero-Murillo L, Diaz-Ruiz A, Guzman-Ruiz R, Catalan V, Rodriguez A, Fruhbeck G, Tinahones FJ, Gasman S, Vitale N, Jimenez-Gomez Y, Malagon MM. The caveolae-associated coiled-coil protein, NECC2, regulates insulin signalling in Adipocytes. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2018; 22(11):5648-5661.
IF: 4,302  
Q: 1

Gomez-Gomez E, Jimenez-Vacas JM, Carrasco-Valiente J, Herrero-Aguayo V, Blanca-Pedregosa AM, Leon-Gonzalez AJ, Valero-Rosa J, Fernandez-Rueda JL, Gonzalez-Serrano T, Lopez-Miranda J, Gahete MD, Castano JP, Requena-Tapia MJ, Luque RM. Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2018; 22(11):5688-5697.
IF: 4,302  
Q: 1

Julia A, Lopez-Longo FJ, Venegas JJP, Bonas-Guarch S, Olive A, Andreu JL, Aguirre-Zamorano MA, Vela P, Nolla JM, de la Fuente JLM, Zea A, Pego-Reigosa JM, Freire M, Diez E, Rodriguez-Almaraz E, Carreira P, Blanco R, Taboada VM, Lopez-Lasanta M, Corbeto ML, Mercader JM, Torrents D, Absher D, Marsal S, Fernandez-Nebro A. Genome-wide association study meta-analysis identifies five new loci for systemic lupus erythematosus. ARTHRITIS RESEARCH & THERAPY. 2018; 20:Núm artículo 100
IF: 4,269  
Q: 2

Garrido-Castro JL, Curbelo R, Mazzucchelli R, Dominguez-Gonzalez ME, Gonzalez-Navas C, Robles BJF, Zarco P, Mulero J, Cea-Calvo L, Arteaga MJ, Font-Ugalde P, Carmona L, Collantes-Estevez E. High Reproducibility of an Automated Measurement of Mobility for Patients with Axial Spondyloarthritis. JOURNAL OF RHEUMATOLOGY. 2018; 45(10):1383-1388.
IF: 3,47  
Q: 2

Tevar-Sanchez M, Navarro-Compan V, Aznar JJ, Linares LF, Castro MC, de Miguel E. Prevalence and characteristics associated with dactylitis in patients with early spondyloarthritis: results from the ESPeranza cohort. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2018; 36(5):879-883.
IF: 3,201  
Q: 2

Moreno M, Gratacos J, Navarro-Compan V, de Miguel E, Font P, Clavaguera T, Linares LF, Joven B, Juanola X. Should over-treatment of axial spondyloarthritis with biologics remain a concern after the issue of the new ASAS criteria? Data from REGISPONSERBIO (Spanish Register of Biological Therapy in Spondyloarthritides). CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2018; 36(6)1038-1042.
IF: 3,201  
Q: 2

Florez MT, Almodovar R, Perez FG, Cambron ABR, Carmona L, Manzanero MAP, Cantalapiedra JA, Urruticoechea-Arana A, Lozano CJR, Castro C, Fernandez-Carballido C, de Miguel E, Galindez E, Vega JLA, Alonso JCT, Linares LF, Moreno M, Navarro-Compan V, Juanola X, Zarco P. The EJES-3D tool for personalized prescription of exercise in axial spondyloarthritis through multimedia animations: pilot study. RHEUMATOLOGY INTERNATIONAL. 2018; 38(7):1277-1284.
IF: 1,952  
Q: 4

Munoz-Fernandez S, Oton-Sanchez T, Carmona L, Calvo-Alen J, Escudero A, Narvaez J, Heredia JMR, Yuste SR, Vela P, Valdes SL, Garcia AR, Baquero JL. Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence. RHEUMATOLOGY INTERNATIONAL. 2018; 38(12):2289-2296.
IF: 1,952  
Q: 4

Gonzalez C, Rodriguez RC, Torre-Alonso JC, Collantes E, Castaneda S, Hernandez MV, Urruticoechea-Arana A, Nieto-Gonzalez JC, Garcia J, Abad MA, Ramirez J, Suarez C, Dalmau R, Martin-Arranz MD, Leon L, Hermosa JC, Obaya JC, Oton T, Carmona L. Recommendations for the Management of Comorbidity in Patients With Axial Spondyloarthritis in Clinical Practice. REUMATOLOGIA CLINICA. 2018; 14(6):346-359.
IF: 0

Molina JT, Alen JC, Ballina J, Belmonte MA, Blanco FJ, Caracuel MA, Carbonell J, Corominas H, Chamizo E, Hidalgo C, Ivorra JR, Marenco JL, Muelas JVM, Munoz-Fernandez S, Nolla JM, Perez T, Sanmarti R, Trenor P, Urrego C, Vidal J, de Salazar JRG. Recommendations for the use of parenteral methotrexate in rheumatic diseases. REUMATOLOGIA CLINICA. 2018; 14(3):142-149.
IF: 0

Almodovar R, Alonso JCT, Batlle E, Castillo C, Collantes-Estevez E, de Miguel E, Gonzalez S, Gratacos J, Hernandez A, Juanola X, Linares LF, Moreno MJ, Moreno M, Navarro-Compan V, Lozano CR, Sanz J, Sellas A, Loza E, Zarco P. Development of a checklist for patients with axial spondyloarthritis and psoriatic arthritis in daily practice: ONLY TOOLS project. REUMATOLOGIA CLINICA. 2018; 14(3):155-159.
IF: 0

Main Publications 2017

Perez-Sanchez C, Aguirre MA, Ruiz-Limon P, Abalos-Aguilera MC, Jimenez-Gomez Y, Arias-de la Rosa I, Rodriguez-Ariza A, Fernandez-del Rio L, Gonzalez-Reyes JA, Segui P, Collantes-Estevez E, Barbarroja N, Velasco F, Sciascia S, Cecchi I, Cuadrado MJ, Villalba JM, Lopez-PedreraC. Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile A Randomized, Placebo-Controlled Trial. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2017.37(10):1923-1932.
IF: 6,607
Q: 1     D: 1

Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, Jimenez-Gomez Y, Arias-de la Rosa I, Abalos-Aguilera MC, Rodriguez-Ariza A, Castro-Villegas MC, Ortega-Castro R, Segui R, Martinez C, Gonzalez-Conejero R, Rodriguez-Lopez S, Gonzalez-Reyes JA, Villalba JM, Collantes-Estevez E, Escudero A, Barbarroja N, Lopez-PedreraC. Diagnostic potential of NETosis-derived products for disease activity, atherosclerosis and therapeutic effectiveness in Rheumatoid Arthritis patients. JOURNAL OF AUTOIMMUNITY. 2017.82:31-40.
IF: 7,641
Q: 1

Ruiz Limón, P. Ortega R, Arias de la Rosa I, Abalos-Aguilera MDC, Perez-Sanchez C, Jimenez-Gomez Y, Peralbo-Santaella E, Font P, Ruiz-Vilches D, Ferrin G, Collantes-Estevez E, Escudero-Contreras A, López-Pedrera C*, Barbarroja N*. Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. TRASLATIONAL RESERACH: the journal of laboratory and clinical medicine. 2017. 183;87-103.
IF: 4,65
Q: 1

López-Medina C, Jiménez-Gómez Y, Moltó A, Schiotis RE, Marzo-Ortega H, van Gaalen FA, Ozgocmen S, Dougados M, Calvo-Gutiérrez J, Castro-Villegas MC, Collantes-Estévez E, Font-Ugalde P; ASAS-COMOSPA taskforce. Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA project. Joint Bone Spine. 2017.  S1297-319X (17)30139-2.
IF: 3,329
Q: 2

Radin M, Cecchi I, Perez-Sanchez C. Antiphospholipid antibodies negativization: time for testing for non-criteria aPL? LUPUS. 2017.26(13):1457-1458.
IF: 2,454
Q: 3

Cardenas MJ, de la Fuente S, Castro-Villegas MC, Romero-Gomez M, Ruiz-Vilchez D, Calvo-Gutierrez J, Escudero-Contreras A, del Prado JR, Collantes-Estevez E, Font P. Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up. RHEUMATOLOGY INTERNATIONAL. 2017.37(10):1701-1708.
IF: 1,824
Q: 3

Lopez-Pedrera C, Aguirre-Zamorano MA, Perez-Sanchez C. Mechanisms of atherosclerosis and cardiovascular disease in antiphospholipid syndrome and systemic lupus erythematosus. New therapeutic approaches. MEDICINA CLINICA. 2017.149(4):160-169.
IF: 1,125
Q: 3

Other Publications 2017

Sciascia S, Coloma-Bazan E, Radin M, Bertolaccini ML, Lopez-Pedrera C, Espinosa G, Meroni PL, Cervera R, Cuadrado MJ. Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion? AUTOIMMUNITY REVIEWS. 2017.16(11):1109-1114.
IF: 8,961
Q: 1        D: 1

Arroyo AB, Salloum-Asfar S, Perez-Sanchez C, Teruel-Montoya R, Navarro S, Garcia-Barbera N, Luengo-Gil G, Roldan V, Hansen JB, Lopez-Pedrera C, Vicente V, Gonzalez-Conejero R, Martinez C. Regulation of TFPI alpha expression by miR-27a/ b-3p in human endothelial cells under normal conditions and in response to androgens. SCIENTIFIC REPORTS. 2017.7():-43500.
IF: 4,259
Q: 1

Aterido A, Julia A, Carreira P, Blanco R, Lopez-Longo JJ, Venegas JJP, Olive A, Andreu JL, Aguirre-Zamorano MA, Vela P, Nolla JM, Marenco-de la Fuente JL, Zea A, Pego JM, Freire M, Diez E, Lopez-Lasanta M, Lopez-Corbeto M, Palau N, Tortosa R, Gelpi JL, Absher D, Myers RM, Fernandez-Nebro A, Marsal S. Genome-wide pathway analysis identifies VEGF pathway association with oral ulceration in systemic lupus erythematosus. ARTHRITIS RESEARCH &THERAPY. 2017.19(1):-138.
IF: 4,121
Q: 2

Gomez-Gomez E, Carrasco-Valiente J, Blanca-Pedregosa A, Barco-Sanchez B, Fernandez-Rueda JL, Molina-Abril H, Valero-Rosa J, Font-Ugalde P, Requena-Tapia MJ. European Randomized Study of Screening for Prostate Cancer Risk Calculator: External Validation, Variability, and Clinical Significance. UROLOGY. 2017.102():85-91.
IF: 2,309
Q: 2

Fernandez-Carballido C, Navarro-Compan V, Castillo-Gallego C, Castro-Villegas MC, Collantes-Estevez E, de Miguel E. Esperanza StudyGrp. Disease Activity As a Major Determinant of Quality of Life and Physical Function in Patients With Early Axial Spondyloarthritis. ARTHRITIS CARE & RESEARCH. 2017.69(1):150-155.
IF: 3,319
Q: 3

Fernandez ASI, Roura XJ, Ruiz AA, Rosas J, Luezas JM, Estevez EC, Hernandez MAA, Benitez VC, Fisac C. Clinical utility of the ASDAS index in comparison with BASDAI in patients with ankylosing spondylitis (Axis Study). RHEUMATOLOGY INTERNATIONAL. 2017.37(11):1817-1823.
IF: 1,824
Q: 3

Torre-Alonso JC, Carmona L, Moreno M, Galindez E, Babio J, Zarco P, Linares L, Collantes-Estevez E, Barrial MF, Hermosa JC, Coto P, Suarez C, Almodovar R, Luelmo J, Castaneda S, Gratacos J. Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain. RHEUMATOLOGY INTERNATIONAL. 2017.37(8):1239-1248.
IF: 1,824
Q: 3

Marras C, Monteagudo I, Salvador G, de Toro FJ, Escudero A, Alegre-Sancho JJ, Raya E, Ortiz A, Carmona L, Mestre Y, Cea-Calvo L, Calvo-Alen J. Identification of patients at risk of non-adherence to oral antirheumatic drugs in rheumatoid arthritis using the Compliance Questionnaire in Rheumatology: an ARCO sub-study. RHEUMATOLOGY INTERNATIONAL. 2017.37(7):1195-1202.
IF: 1,824
Q: 3

Bonilla PN, Gomez RG, Jimenez DR, Fabra MLV, Villanueva MDM, Catalan RG, Ugalde FF, Fernandez MSP, Alonso JLL, Galera JMG. Enhanced depth OCT imaging of the lamina cribrosa for 24 hours. INTERNATIONAL JOURNAL OF OPHTHALMOLOGY. 2017.10(2):306-309.
IF: 1,177
Q: 4

Clinical Research

Active in 2019

A multicenter, randomized, placebo-controlled, double-blind, parallel-group phase III study to assess the efficacy and safety of Apremilast (CC-10004) in the treatment of active ankylosing spondylitis.
PI: Dr Eduardo Collantes Estévez

A randomized, double-blind, placebo-controlled, 52-week duration study to assess adverse events of special interest in adults with systemic antibody positive lupus erythematosus receiving belimumab.
PI: Dr Mª Ángeles Aguirre Zamorano

A Phase III, randomized, double-blind, placebo controlled multi-center study of subcutaneous secukinumab (150 mg and 300 mg) in prefilled syringe to demonstrate efficacy (including inhibition of structural damage), safety, and tolerability up to 2 years in subjects with active psoriatic arthritis (FUTURE 5).
PI: Dr Mª Dolores López Montilla

Assessing cardiovascular risk and its determinants in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
PI: Dr  Eduardo Collantes Estévez

Multi-Country Registry of clinical characteristics, including radiographic progression, and burden of disease over 5 years in real-life setting) PROOF.
PI: Dr Eduardo Collantes Estévez

ASCORE study about long-term experience with abatacepts.c. in habitual clinical practice.
PI: Dr Alejandro Escudero Contreras

Spanish Registry of psoriatic arthritis.
PI: Dr Mª Dolores López Montilla

Spanish Registry of adverse events in biological and biosimilar therapies in rheumatic illnesses. Phase III.
PI: Dr Eduardo Collantes Estévez

A Multi-Center Observational Study to Evaluate the Real-life effectiveness of Benepali following transition from Enbrel in patients with Rheumatoid Arthritis and Axial Spondyloarthritis. (The Benefit Study)
PI: Dr María Del Carmen Castro Villegas

Early treatment with biological therapy in axial spondyloarthritis: 5-year effectiveness.
PI: Dr María Del Carmen Castro Villegas

A multicenter, prospctive, observational cohort study to evaluate the real-world safety and effectiveness of Erelzi, an etanercept biosimilar (COMPACT)
PI: Dr María Del Carmen Castro Villegas

Estudio multicéntrico, observacional no intervencionista, transversal y retrospctivo, para evaluar el control de la actividad de la enfermedad en condiciones de práctica clínica habitual en pacientes con Espondilitis Anquilosante y Artritis Psoriásica tra
PI: Dr María Del Carmen Castro Villegas

Estudio prospectivo, multicéntrico para evaluar la eficacia y la seguridad de una inyección única de hialuronato sódico en pacientes con artrosis de rodilla
PI: Dr Miguel Ángel Caracuel Ruiz

Estudio de adaptación del cuestionario Qualisex para pacientes con artritis reumatoide en España.
PI: Dr. Miguel Ángel Caracuel Ruiz

Sensibilkidad al cambio del índice UCOASMI en pacientes con espondiloartritis axial y enfermedad activa según el índice BASDAI (estudio UCOTRACK-II).
PI: Dr. Eduardo Collantes Estévez

A Multicenter, Open-label (Part A) Followed by a Randomized, Double-blind, Parallel-group, Placebo Controlled Study (Part B) to Evaluate Maintenance of Remission in Subjects With Active Axial Spondyloarthritis (axSpA) Receiving Either Certolizumab Pegol 200 mg Q2W or 200 mg Q4W as Compared to Placebo
PI: Dr Eduardo Collantes Estévez

A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU.
PI: Dr Eduardo Collantes Estévez

A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs).
PI: Dr Alejandro Escudero Contreras

A Multicenter Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis.  
PI: Dr Eduardo Collantes Estévez

A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis       
PI: Dr Mª Dolores López Montilla

Ensayo de fase IV, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de golimumab (MK-8259 [SCH 900259]) tras la retirada del tratamiento, en comparación con su continuación.
PI: Dr Eduardo Collantes Estévez

A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab to Evaluate the Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Non-radiographic Axial Spondyloarthritis.
PI: Dr María del Carmen Castro Villegas

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis. 
PI: Dr Mª Dolores López Montilla

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase II Study to Evaluate The Safety and Efficacy of RO7123520 as Adjunct Treatment in Patients With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to TNF-alpha Inhibitors.               
PI: Dr Alejandro Escudero Contreras

A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD),
PI: Dr Mª Dolores López Montilla

Estudio de Extensión, Abierto, Multicéntrico, para Evaluar la Seguridad y Eficacia a Largo Plazo de Bimekizumab en Pacientes con Espondilitis Anquilosante.
PI: Dr. Eduardo Collantes Estévez

Estudio Multicéntrico, aleatorizado, en doble ciego, controlado con placebo y grupos paralelos, de ustekinumab en sujetos con eritematoso sistemático activo.
PI: Dr Mª Ángeles Aguirre Zamorano

Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de sarilumab en pacientes con arteritis de células gigantes.
PI: Dr. Alejandro Escudero Contreras

Efectos de ABATACEPT enla progresión de la artritis reumatoide en pacientes con reumatismo palindrómico (PALABA).
PI: Dr. Alejandro Escudero Contreras

Ensayo fase 3b, multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de guselkumab administrado subcutáneo en pacientes con Artritis Psoriásica activa y con una respuesta inadecuada a la terapia con Factor .
PI: Dr. Mª Dolores López Montilla

Estudio de fase 3, multicéntrico, aleatorizado, en doble ciego y controlado con placebo, para evaluar la eficacia y seguridad de BIMEKIZUMAB en sujetos con espondiloartritis axial activa no radiográfica.
PI: Dr. María Del Carmen Castro Villegas

Estudio de fase 3, multicéntrico, aleatorizado, en doble ciego y controlado con placebo, para evaluar la eficacia y seguridad de BIMEKIZUMAB en sujetos con espondilitis anquilosante activa
PI: Dr. María Del Carmen Castro Villegas

Estudio multicéntrico, aleatorizado, controlado con placebo, con doble enmascaramiento, para evaluar la eficacia y la seguridad de dosis múltiples de BMS-986165 en sujetos con artritis psoriásica (AP) activa.
PI: Dr. Alejandro Escudero Contreras

Estudio en fase III, multicéntrico, aleatorizado, doble ciego, de 24 semanas de duración, para comparar la eficacia y la seguridad de GSK3196165 con placebo y con sarilumab, en combinación con FARME sintéticos convencionales, en participantes con artritis.
PI: Dr. Alejandro Escudero Contreras

Estudio en fase III, multicéntrico, aleatorizado, doble ciego, de 52 semanas de duración, para comparar la eficacia y la seguridad de GSK3196165 con placebo y con tofacitinib, en combinación con metotrexato, en participantes con artritis reumatoide con ac.
PI: Dr. Alejandro Escudero Contreras

Members

Dr. Eduardo Collantes Estévez

Co-Principal Investigator

Team

Nuria Barbarroja Puerto Mª Ángeles Aguirre Zamorano Miguel Ángel Caracuel Ruiz Alejandro Escudero Contreras Pilar Font Ugalde Inmaculada Gómez Gracia María Dolores López Montilla Verónica Pérez Guijo Jerusalem Calvo Gutierrez Mª Del Carmen Castro Villegas Alejandro Ibañez Costa Yolanda Jiménez Gómez Clementina López Medina Rafaela Ortega Castro Carlos Pérez Sánchez Alejandra Maria Patiño Trives Iván Arias de la Rosa Luis Jurado Ruiz Rocío Segura Ruiz Mª Carmen Ábalos Aguilera María Dolores Romero Gutiérrez Desiree Ruiz Vílchez